Posaconazole-increased vincristine neurotoxicity in a child: A case report

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 4, 2009, Pages 292-295

  Eiden, Céline ^a   Palenzuela, Gilles ^b   Hillaire Buys, Dominique ^a   Margueritte, Geneviève ^b   Cociglio, Marylène ^a   Hansel Esteller, Sylvie ^c   Peyriere, Hélène ^a,c  

^a Department of Medical Pharmacology and Toxicology ^*  (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c LAPEYRONIE HOSPITAL   (France)

Author keywords

Drug interaction; Neurotoxicity; Posaconazole; Secondary antifungal prophylaxis; Vincristine

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ASPARAGINASE; CASPOFUNGIN; CYTARABINE; CYTOCHROME P450 3A4; DEXAMETHASONE; GLYCOPROTEIN P; METHOTREXATE; POSACONAZOLE; PREDNISONE; VINCRISTINE; VORICONAZOLE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; TRIAZOLE DERIVATIVE;

ABDOMINAL CRAMP; ACUTE LYMPHOBLASTIC LEUKEMIA; AREFLEXIA; ARTICLE; CANCER RELAPSE; CASE REPORT; CHILD; CONSCIOUSNESS DISORDER; CONSTIPATION; DROWSINESS; DRUG METABOLISM; DRUG TRANSPORT; DRUG WITHDRAWAL; FEMALE; FUSARIOSIS; HUMAN; HYPONATREMIA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRESCHOOL CHILD; PRIORITY JOURNAL; SEIZURE; SPEECH DISORDER; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG INTERACTION; MYCOSIS; NEUROLOGIC DISEASE; RECURRENT DISEASE;

ANTIBIOTICS, ANTIFUNGAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HUMANS; MYCOSES; NERVOUS SYSTEM DISEASES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; TRIAZOLES; VINCRISTINE;

EID: 65349168038     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31819b9d01     Document Type: Article

References (19)

1. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol. 2007;78:275-283.
2. Maertens J, Frere P, Lass-Florl C, et al. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer. 2007;5(Spl): 43-48.
3. Prise en charge des candidoses et aspergilloses invasives de l'adulte. Conférence de Consensus commune organisée con-jointement par la SFAR, la SPILF et la SRLF. Texte long. Med Mal Infect. 2005;35:48.
4. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-359.
5. Keating GM. Posaconazole. Drugs. 2005;65:1553-1567.
6. Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004;21: 645-653.
7. Allinson K, Klove H, Gumbinger HG, et al. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother. 2008;61:734-742.
8. Gupta S, Almyroudis NG, Battiwalla M, et al. Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation. Transplant Infect Dis. 2007;9:156-160.
9. Krishna G, Sansone-Parsons A, Martinho M, et al. Posaco-nazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother. 2007;51: 812-818.
10. Stuart MJ, Cuaso C, Miller M, et al. Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine. Blood. 1975;45:315-320.
11. Sathiapalan RK, El-Solh H. Enhanced vincristine neurotoxi-city from drug interactions: case report and review of literature. J Pediatr Hematol Oncol. 2001;18:543-546.
12. Bermudez M, Fuster JL, Llinares E, et al. Itraconazole-related increased vincristine neurotoxicity: a case report and review of literature. J Pediatr Hematol Oncol. 2005;27:38-39.
13. Kamaluddin M, Mc Nally P, Breatnach F, et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr. 2001;90:1204-1207.
14. Mantadakis E, Amoiridis G, Kondi A, et al. Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. J Pediatr Hematol Oncol. 2007;29:130.
15. Wang EJ, Lew K, Casciano CN, et al. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 2002;46:160-165.
16. Verstappen C, Heimans J, Hoekman K, et al. Neurotoxic complications of chemotherapy in patients with cancer. Drugs. 2003;63:1549-1563.
17. Kiu MC, Liaw CC, Yang TS, et al. Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma. Anticancer Drugs. 1994; 5:480-482.
18. Peyriere H, Poiree M, Cociglio M, et al. Reversal of neurologic disturbances related to high-dose methotrexate by aminophylline. Med Pediatr Oncol. 2001;36:662-664.
19. Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology. 2003;60:337-340.